A Double-Blind, 2-Way Crossover Study to Investigate the Effects of JNJ-40411813 on Ketamine-Induced Alterations in Neuropsychiatric Performance.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2015
At a glance
- Drugs ADX 71149 (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 15 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2010 Actual patient number is 40 as reported by ClinicalTrials.gov.
- 14 Apr 2010 New trial record